Xilio Therapeutics, Inc. (NASDAQ: XLO) reported Q1 EPS of ($0.18), $0.37 worse than the analyst estimate of $0.19.

For earnings history and earnings-related data on Xilio Therapeutics, Inc. (XLO) click here.